Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corcept Therapeutics (CORT) Cash from Investing Activities: 2009-2025

Historic Cash from Investing Activities for Corcept Therapeutics (CORT) over the last 10 years, with Sep 2025 value amounting to $14.6 million.

  • Corcept Therapeutics' Cash from Investing Activities rose 133.26% to $14.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $17.2 million, marking a year-over-year increase of 117.93%. This contributed to the annual value of -$177.6 million for FY2024, which is 295.37% down from last year.
  • Per Corcept Therapeutics' latest filing, its Cash from Investing Activities stood at $14.6 million for Q3 2025, which was down 79.12% from $70.1 million recorded in Q2 2025.
  • In the past 5 years, Corcept Therapeutics' Cash from Investing Activities registered a high of $207.5 million during Q1 2023, and its lowest value of -$109.6 million during Q3 2023.
  • For the 3-year period, Corcept Therapeutics' Cash from Investing Activities averaged around -$463,364, with its median value being -$9.0 million (2024).
  • Its Cash from Investing Activities has fluctuated over the past 5 years, first soared by 1,151.97% in 2021, then crashed by 2,187.47% in 2023.
  • Over the past 5 years, Corcept Therapeutics' Cash from Investing Activities (Quarterly) stood at $140.5 million in 2021, then plummeted by 112.27% to -$17.2 million in 2022, then skyrocketed by 199.17% to $17.1 million in 2023, then plummeted by 476.42% to -$64.4 million in 2024, then spiked by 133.26% to $14.6 million in 2025.
  • Its Cash from Investing Activities was $14.6 million in Q3 2025, compared to $70.1 million in Q2 2025 and -$3.2 million in Q1 2025.